The 3M roles of the gut microbiome in pharmacotherapy for diabetes: mediator, modifier, and marker

Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0

초록

The rising global prevalence of type 2 diabetes mellitus (T2DM) presents major challenges to healthcare systems; thus, more effective treatment strategies are urgently needed. In this context, the growing recognition of the gut microbiome’s role in T2DM pharmacotherapy has shifted attention toward integrating microbiome-derived mechanisms to optimize drug response. This review proposes a structured ‘3M’ framework that classifies the gut microbiome’s roles in T2DM pharmacotherapy into three translational categories: mediator of drug action, modifier of therapeutic response, and marker for predicting efficacy or intolerance, based on recent clinical and mechanistic insights. Together, these insights support a translational framework that may guide the integration of microbiome-informed strategies into future T2DM pharmacotherapy. © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.; AbstractThe rising global prevalence of type 2 diabetes mellitus (T2DM) presents major challenges to healthcare systems; thus, more effective treatment strategies are urgently needed. In this context, the growing recognition of the gut microbiome’s role in T2DM pharmacotherapy has shifted attention toward integrating microbiome-derived mechanisms to optimize drug response. This review proposes a structured ‘3M’ framework that classifies the gut microbiome’s roles in T2DM pharmacotherapy into three translational categories: mediator of drug action, modifier of therapeutic response, and marker for predicting efficacy or intolerance, based on recent clinical and mechanistic insights. Together, these insights support a translational framework that may guide the integration of microbiome-informed strategies into future T2DM pharmacotherapy. © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

키워드

antidiabetic drugsdiabetesgut microbiomepharmacomicrobiomicsGLYCEMIC CONTROLDOUBLE-BLINDMETFORMINASSOCIATIONSERUMHOMEOSTASISMETAGENOMEBACTERIAACARBOSEOBESITY
제목
The 3M roles of the gut microbiome in pharmacotherapy for diabetes: mediator, modifier, and marker
저자
Seo, J.I.Koh, A.Lim, S.Yoo, H.H.
DOI
10.1016/j.tem.2025.12.006
발행일
2026-07
유형
Article
저널명
Trends in Endocrinology and Metabolism
37
7
페이지
624 ~ 638